KL and hypophosphatemia: However, emerging evidence from clinical trials has revealed that klotho therapies may disrupt Ca2+ homeostasis by controlling parathyroid hormone (PTH) secretion, and intravenous infusion of klotho may also cause hypophosphatemia and phosphaturia [96–98].